CHYMOLEPSIN

Instructions on medical use of the drug

Trade name: Himolepsin.

International nonproprietary name: Trypsin + Chymotrypsin.

Dosage form: enteric - coated tablets.

Composition: *Each enteric-coated tablet contains:*

Active substances: a purified concentrate containing trypsin and chymotrypsin in a ratio of approximately

six to one.

Enzyme activity......100000 AU.

Pharmaco - therapeutic group: Enzymes in combinations.

ATX code: M09AB52. Pharmacological properties:

Pharmacodynamics:

Proteolytic combined drug of protein nature. Obtained from the pancreas gland of cattle.

Trypsin is an enzyme preparation with proteolytic action, obtained from the pancreas of cattle. Trypsin has pronounced anti-inflammatory and anti-edema properties, properties, is able to break down dead tissue, fibrinous formations, viscous secretions and exudates. The enzyme is inactive and safe in relation to healthy tissues due to the presence of trypsin inhibitors (specific and nonspecific) in them. Does not affect the hemostatic system.

Chymotrypsin, a proteolytic enzyme obtained from the pancreas of cattle, hydrolyzes predominantly bonds formed by tyrosine, phenylalanine and other aromatic amino acid residues. Breaks down peptide bonds in the protein molecule and its breakdown products. It has an anti-inflammatory effect, since inflammatory factors are proteins or high-molecular peptides (bradykinin, serotonin, necrotic products, etc.). Licks necrotic tissues, without affecting viable cells, due to the presence of specific antienzymes in them.

Pharmacokinetics:

Not studied.

Indications for use:

For respiratory diseases: tracheitis, bronchitis, bronchiectasis, pneumonia, lung abscesses, bronchial asthma in order to thin thick viscous sputum, sanitize the respiratory tract and quickly stop the inflammatory process, for better penetration of antibiotics into the source of infection;

In surgical practice: in the treatment of third-degree burns, for the purpose of preventing postoperative complications during lung operations for malignant neoplasms, chronic inflammatory processes, thrombophlebitis, bacterial infection of the skin and subcutaneous tissue, for resorption of hematomas, for pain after surgery, for the purpose of rejection of necrotic fabrics;

In traumatology: for fractures, injuries of muscles and tendons;

In ophthalmology: for diseases of the cornea (ulcers, herpetic keratitis) in order to reject necrotic layers and accelerate regeneration, for burns of the mucous membrane, in fresh cases of obstruction of the lacrimal ducts, with sluggish healing of eyelid skin wounds;

In otorhinolaryngology: to improve the penetration of antibiotics in chronic respiratory diseases, purulent sinusitis, purulent otitis (acute, subacute, chronic) with the presence of viscous exudate, after tracheostomy to facilitate the removal of thick viscous exudate, in chronic rhinitis;

In gynecology and urology: for chronic recurrent infectious and inflammatory diseases of the female genital area, for chronic prostatitis, episiotomy, recovery after cesarean section, hysterectomy;

In dentistry: to improve the transport of antibiotics to the site of inflammation and eliminate inflammatory edema (acute and chronic periodontitis, pulpitis);

Also used: for burns, bedsores, trophic ulcers, purulent wounds.

Contraindications:

- hypersensitivity to the components of the drug;
- peptic ulcer of the gastrointestinal tract;
- severe liver or kidney diseases;
- mechanisms of blood coagulation disorders and hemorrhagic diathesis;
- malignant neoplasms;
- destructive forms of pulmonary tuberculosis;
- cardiac and respiratory failure;
- patients receiving anticoagulants.

Directions for use and dosage: The tablets are taken orally without chewing. It is recommended to take the tablets at least 30 minutes before meals, without chewing, with plenty of water (200 ml). Take 1 tablet of Himolepsin orally 4 times a day. After injury, treatment should begin as early as possible. The course of therapy for acute diseases is from 2 weeks until recovery, and for exacerbations of chronic diseases, treatment continues until there are clear signs of remission. The average duration of treatment lasts from 2 weeks to 3 months, as directed by the attending physician.

Side effects:

Possible allergic reactions, increased body temperature to subfebrile, tachycardia. *Rarely: stomach* upsets.

Overdoses

In case of accidental overdose there is no risk of developing unwanted side effects and overdose is unlikely.

Drug interactions:

When used simultaneously with iron supplements, iron absorption may be reduced.

Special instructions:

Pregnancy and lactation:

During pregnancy and lactation, the use of the drug should be treated with the usual caution for this condition. Use is possible after a doctor has assessed the ratio of benefit to the mother / risk to the fetus / child. Use with caution in patients with enzyme sensitivity.

Release form:

20 enteric-coated tablets in each blister. One blister along with instructions for use in cardboard packaging.

Storage conditions:

Store in a dry place, protected from light, at a temperature not exceeding $25\,^{\circ}$ C and out of the reach of children.

Expiration date:

Indicated on the packaging. Do not use after expiration date.

Conditions of release:

By doctor's prescription.

Made for:

MAXX-PHARM LTD.

London, Great Britain